Merck prepared to shell out $27.7M for Fosamax suits; Boehringer failed to preserve Pradaxa files;

@FiercePharma: Teva braces for a $550M hit from Copaxone generics. Story | Follow @FiercePharma

@EricPFierce: As this story says, Merck was getting heat on Fosamax litigation it is now settling. News | Follow @EricPFierce

@CarlyHFierce: Pfizer loses Supreme Court bid to squash $142M Neurontin verdict. More | Follow @CarlyHFierce

> Merck ($MRK) says it's prepared to fork over $27.7 million to settle lawsuits with those who claim its osteoporosis drug Fosamax caused their jaw bones to deteriorate. Report

> Boehringer Ingelheim will pay a $931,000 fine for failing to preserve files related to the development and marketing of blood thinner Pradaxa. Report

> The EU has granted marketing authorization to Novo Nordisk ($NVO) for its hemophilia drug NovoEight. Report

> Eli Lilly ($LLY) has entered into India's branded generics segment with the launch of four cancer drugs. Report

> New Forest Laboratories ($FRX) CEO Brent Saunders is putting together a new team to carry out the restructuring announced last week. Release

> Lupin has received final FDA approval for its copy of ViiV Healthcare's HIV-fighting Trizivir tablets. Report

Medical Device News

@FierceMedDev: Edwards looks to a rocky 2014 as Medtronic looms. More | Follow @FierceMedDev

@MarkHFierce: $100M gets CareFusion a minority stake in an Israeli infusion pump maker--they're old friends as well. Story | Follow @MarkHFierce

@MichaelGFierce: New Hologic CEO aims for Dx revenue growth over sale option. Item | Follow @MichaelGFierce

@GalenMoore: Genetic testing: Invitae completes a $40 million series E financing. Release | Follow @GalenMoore

> St. Jude Medical will try again another day for U.S. renal denervation study. More

> Disgraced founder, former exec team sentenced in PIP breast implant scandal. Story

Biotech News

@FierceBiotech: Alzheimers R&D: The biggest lottery in the industry, with a winning ticket worth an overnight fortune. Story | Follow @FierceBiotech

@JohnCFierce: So what are the 5 worst pharma media ops? Novartis certainly makes the list. Merck of course. Other suggestions? | Follow @JohnCFierce

@DamianFierce: The FDA's still wary of dapagliflozin, AstraZeneca and Bristol-Myers Squibb's once-rejected diabetes drug. More | Follow @DamianFierce

@EmilyMFierce: Nobel winner declares boycott of top science journals. Story via The Guardian | Follow @EmilyMFierce

> AbbVie's second PhIII hep C study confirms cocktail's promise. Item

> Danish officials cite Novo Nordisk for delay of game. Article

> Takeda sways FDA panel with its bowel disease drug despite viral risks. More

> FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin. News

Pharma Manufacturing News

> Track-and-trace is here ... and now. Editor's corner

> FDA spanks a second Jubilant HollisterStier plant. More

> Alvogen makes a $250M biosimilars investment in Iceland. Story

> Biogen API plant gets nicked by the FDA. Article

> Hospira cuts costs by expanding drug and API production outside of the U.S. News

> Pharma Tech adds capacity as the CMO industry heats up. Report

> Feds close down importer that sold unapproved Botox and cancer drugs. Item

Biotech Research News

> Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. More

> GlaxoSmithKline initiates global cancer consortium. Item

> Report: Global malaria R&D needs $8.3B boost over next decade. Story

> Gene discovery could predict responsiveness of antidepressants. Report

> International Stem Cell Corp. finds a new way to reprogram cells. News

> 1 in 100 cancers associated with gene mutation. Article

And Finally... Some scientists in Israel are advocating for what could be the first nationwide screening campaign to test women for cancer-causing genetic mutations commonly found among Jews. Story (sub. req.)

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.